A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma

Daniel Reinhorn, Michal Sarfaty*, Moshe Leshno, Assaf Moore, Victoria Neiman, Eli Rosenbaum, Daniel A. Goldstein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences